FIT Biotech Oy: FIT Biotech to explore possibiliti

FIT BIOTECH OY

Company release April 25, 2017 at 8:30 AM EET                                                            

FIT Biotech to explore possibilities for secondary listing to First North Sweden -market

The Board of Directors of FIT Biotech, a First North Finland listed company, has made a decision to explore possibilities to apply for secondary listing for its shares in the First North Sweden market. The objective for the secondary listing would be to facilitate trading liquidity for the Company's current and future shareholders.

The Chairman of the Board Rabbe Slätis comments: "FIT Biotech offers investors an unprecedented opportunity to participate in the international commercialization of drug candidates based on Finnish biotechnology aiming at improving human health and affordability of therapy. With the potential secondary listing we wish to offer an easy access to trading with FIT Biotech's shares to those investors trading through Stockholm Stock Exchange First North market. While drug development is an inherently long-term process, there should be multiple milestones met along the way enabling licensing agreements at early stage of development. We believe FIT Biotech would be an interesting investment opportunity also in the First North Sweden market."

Chief Executive Officer James Kuo comments: "Our recent research progress and internal process development would in our opinion enable the secondary listing. According to the decision of our Board of Directors we are investigating the possibility for applying listing also to First North Sweden market. We believe the potential secondary listing would provide us an excellent tool to expose the company also to new investors interested in biotechnology."

FIT BIOTECH OY

Further information: Rabbe Slätis Chairman of the Board FIT Biotech Oy Tel: +358 40 8406749 E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION: Nasdaq Helsinki Principal media